From microRNA modulators to anti-TL1A therapies, the pipeline of IBD therapies is evolving fast. New mechanisms could reshape how we treat Crohn’s and ulcerative colitis. 🚀🧪Dr. Bruce Sands of @IcahnMountSinai reviewed what’s on the horizon at #DDW2026. #GITwitter
The stats on #MASLD and MASH are staggering! So many people are affected and yet so few discover it until advanced disease. Truly hoping #MedTwitter pays attention to this #DDW2026 session.
Liver disease affects ~1 in 3 Americans — yet most go undiagnosed until advanced stages. 🫀 With a shortage of liver specialists, GI & primary care providers must play a role in screening and managing these patients, says @RobertFontanaMD of @MichiganLiver. 🩺 #DDW2026 #MASH #MASLD #LiverDisease @UMichMedicine #LiverTwitter #GITwitter
From semaglutide to tirzepatide—and now oral options—the obesity treatment landscape is shifting fast. But success depends on more than the drug: adherence, side-effect mitigation, and multidisciplinary care are key, says Dr. Robert Kushner of @NUFeinbergMed. #GLP-1 #Obesity #GITwitter
@DDWMeeting Really eye-opening findings on what might raise your risk of early-onset colorectal cancer. Interesting research presented by @MingyangSong3 at #DDW2026.
Speaking out or taking a stand is complicated and requires strategic planning. For expertise on protecting organizations’ reputations, read our new blog from Senior Counselor Christine Stencel, MA, “Organizational Positioning in Turbulent Times,” https://t.co/UOUaHtdEu1.
@moen could not find on your website the answer to my Q about Koa faucet. Just need to know if it swivels at the base when mounted without the deckplate?
It's fascinating to think it wasn't long ago that we were watching TV characters routinely quaff huge glasses of wine on shows like Cougar Town. I'm curious to see how the science and warnings affect behavior.
@bylenasun Per this morning's WP Health Brief, I echo your wish to not face nightmares about emerging viruses! I fear they aren't going away soon alas.
Conducting Comparative Effectiveness, Multisite Palliative Care and Advance Care Planning Trials: Lessons Learned and Future Directions From PCORI-Funded Studies https://t.co/MrKY7S2jrw
@NatlParkService And the 3rd of that win win win you mentioned is that the gnarly little bloodsuckers get dead! Sure, everything has its place and role, but ticks are the nasty exception!
Findings from a community-engaged @PCORI project led by @AnaProgovac@Dharmisima and @herlab_equity are out now in Health Services Research.
https://t.co/FDGWPlDJMM
We know that racial/ethnic discrimination negatively impacts patient care. How should providers address this?
We are excited to share the progress of our "Missing Pieces Trial," funded by @PCORI. Over the past year, we have laid the groundwork to connect bereaved parents with community resources, helping them navigate their grief. Learn more about this work: https://t.co/M7G0ChlZSa
These are informative secondary findings from the @PCORI-funded HERO study comparing treatment strategies for #HCV infection among people who are at highest risk b/c they inject drugs. The trial showed both treatment approaches compared achieved comparably high cure rates.
IMHO, the headline of this great article stressed the wrong thing. While hep C reinfection occurs after injection drug users are cured, it's to be expected considering they're a super-high-risk population & rates of reinfection were smaller over time. https://t.co/2fsg0zWUpR
📢 FUNDING PRE-ANNOUNCEMENT | @PCORI will soon announce a funding opportunity for its Broad Pragmatic Studies, which will include a special area of emphasis on #SocialIsolation and Loneliness in #OlderAdults.
Learn more: https://t.co/FHPpxT1T8c